Lipoprotein and protein binding of the calcium channel blocker diltiazem.
The plasma protein binding properties of the calcium channel blocker diltiazem were studied using a three-chamber equilibrium dialysis system. Diltiazem is 81% bound to human sera with significant inter-individual variation. The relative binding of diltiazem by lipoproteins and alpha 1-acid glycoprotein was higher than by albumin. The binding to low density lipoprotein was strong and appeared not to be associated with the surface apoprotein.
D001552:Benzazepines / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism*; D011232:Chemical Precipitation; D003956:Dialysis; D004110:Diltiazem / Q000378:metabolism*; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism; D011485:Protein Binding; D014238:Trichloroacetic Acid
D001552:Benzazepines; D001798:Blood Proteins; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D014238:Trichloroacetic Acid; D004110:Diltiazem